Nanovery is developing liquid nanorobots that detect DNA and RNA biomarkers in liquid samples, providing precise quantification of nucleic acids. This technology addresses the challenges of traditional nucleic acid testing by simplifying workflows and reducing time and costs associated with biomarker analysis.
Funding
$4.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional methods for quantifying nucleic acids, such as DNA and RNA biomarkers, often involve complex workflows, lengthy processing times, and high costs, hindering efficient biomarker analysis. These limitations can impede research and development in areas like RNA therapeutics and disease diagnostics.
Solution
Nanovery is developing liquid nanorobots that simplify and accelerate the detection and quantification of nucleic acid biomarkers in liquid samples. These nanorobotic sensors, built using DNA nanotechnology, are designed to bind to specific DNA or RNA sequences within a sample. Once bound, the nanorobots emit a fluorescent signal that can be measured to determine the absolute concentration of the target nucleic acid. This approach reduces sample preparation, shortens assay times, and lowers overall costs compared to traditional nucleic acid testing methods.
Target Audience
The primary target audience includes biotechnology researchers and developers involved in nucleic acid research, RNA therapeutics, and biomarker quantification.
Features
- Nanorobotic sensors designed for specific DNA and RNA biomarker detection
- Simplified two-step workflow: add nanorobots to the sample, then measure fluorescence
- High accuracy in quantifying nucleic acid sequences
- Customizable nanorobots tailored to specific research needs
- Potential applications in ASO bioanalysis and siRNA bioanalysis